HC Wainwright & Co. Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $243
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Joseph Pantginis maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and raises the price target from $239 to $243.
HC Wainwright & Co. analyst Joseph Pantginis maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and raises the price target from $239 to $243.